Delivery Order SPE2DB24D1021-SPE2DB25FEZYX
- Not listed
- The Defense Logistics Agency awarded a $68,784.07 delivery order to AmerisourceBergen Drug Corp for the supply of Entresto 49 mg-51 mg tablets (180-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a direct fulfillment under the company's broader pharmaceutical supply arrangements. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $3,689.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Entresto 24 mg-26 mg tablets (60-count supply) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-competitive delivery order was placed against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled at...
- The Defense Logistics Agency awarded a delivery order valued at approximately $24,925 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180 count) under a firm fixed-price contract. The award was made on August 15, 2025, with an ultimate completion date of August 18, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance for this pharmaceutical delivery order....
- The Defense Logistics Agency awarded a $2,342.93 delivery order to AmerisourceBergen Drug Corp for 180 tablets of Entresto 24 mg-26 mg on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $7,996.94 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 97 mg-103 mg tablets (180-count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 29, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count supply) with a ceiling value of $51,539.65. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a competitively awarded contract with no set-aside designation. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $12,618.73 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180-count units). This firm fixed-price, competitively awarded delivery order was issued on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $12,336.96 to AmerisourceBergen Drug Corp for Entresto 24 mg-26 mg tablets (60-count packaging) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, competitively awarded delivery order was issued with no set-aside designation and represents a direct procurement of a brand-name pharmaceutical product for federal medical supply needs. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count) valued at $3,510.76. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and is scheduled for completion by July 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this pharmaceutical supply transaction, which will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order valued at $13,992.61 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEZYXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,134.39 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets in a quantity of 60 units. This competitive award, executed on August 22, 2025, with an ultimate completion date of August 25, 2025, represents a firm fixed price delivery order with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The DLA Troop Support Medical Supply Chain utilizes this framework to fulfill recurring pharmaceutical needs across the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems, with Entresto—a cardiac medication—being one of many therapeutic categories supported under the agreement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 8/22/25 |